Loading…
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $54M | $-467M | $-413M | $-387M | -34.6% | 48.0% | -161.3% |
| 2024 | $36M | $-420M | $674M | $-392M | 43.7% | 36.1% | -291.4% |
| 2023 | $27M | $-385M | $-352M | $-315M | -43.4% | 88.4% | 51.9% |
| 2022 | $14M | $-380M | $-232M | $-314M | -21.1% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 14.24 | 26.82 | 36.50 | 54.03 |
| Operating Revenue | - | 14.24 | 26.82 | 36.50 | 54.03 |
| Cost Of Revenue | - | 1.70 | 2.88 | 4.16 | 6.34 |
| Gross Profit | - | 12.54 | 23.94 | 32.33 | 47.68 |
| Operating Expense | - | 401.58 | 415.43 | 458.07 | 519.82 |
| Research And Development | - | 279.91 | 295.53 | 301.29 | 339.54 |
| Selling General And Administration | - | 121.67 | 119.90 | 156.78 | 180.28 |
| Total Expenses | - | 403.29 | 418.31 | 462.24 | 526.16 |
| Operating Income | - | -389.05 | -391.49 | -425.74 | -472.13 |
| Total Operating Income As Reported | - | -389.05 | -391.49 | -425.74 | -472.13 |
| EBITDA | - | -380.48 | -384.86 | -420.08 | -466.96 |
| Normalized EBITDA | - | -518.19 | -384.86 | -1,509.22 | -466.96 |
| EBIT | - | -389.05 | -391.49 | -425.74 | -472.13 |
| Interest Income | - | 12.79 | 33.34 | 48.08 | 56.38 |
| Net Interest Income | - | 12.79 | 33.34 | 48.08 | 56.38 |
| Other Non Operating Income Expenses | - | 6.75 | 6.06 | 6.49 | 1.96 |
| Other Income Expense | - | 144.45 | 6.06 | 1,095.62 | 1.96 |
| Interest Income Non Operating | - | 12.79 | 33.34 | 48.08 | 56.38 |
| Net Non Operating Interest Income Expense | - | 12.79 | 33.34 | 48.08 | 56.38 |
| Pretax Income | - | -231.80 | -352.09 | 717.97 | -413.80 |
| Tax Provision | - | 0 | 0 | 44.24 | -1.02 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 67.12 | 0 |
| Net Income Continuous Operations | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Net Income From Continuing And Discontinued Operation | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Net Income From Continuing Operation Net Minority Interest | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Net Income | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Net Income Common Stockholders | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Net Income Including Noncontrolling Interests | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Normalized Income | - | -369.50 | -352.09 | -348.29 | -412.78 |
| Diluted NI Availto Com Stockholders | - | -231.80 | -352.09 | 673.72 | -412.78 |
| Basic Average Shares | - | 54.79 | 55.65 | 56.81 | 57.97 |
| Diluted Average Shares | - | 54.79 | 55.65 | 57.89 | 57.97 |
| Reconciled Depreciation | - | 8.56 | 6.62 | 5.65 | 5.18 |
| Reconciled Cost Of Revenue | - | 1.70 | 2.88 | 4.16 | 6.34 |
| Total Unusual Items | - | 137.70 | 0 | 1,089.14 | 0 |
| Total Unusual Items Excluding Goodwill | - | 137.70 | 0 | 1,089.14 | 0 |
| Net Income Discontinuous Operations | 1,961.22 | 0 | 0 | - | - |
| Special Income Charges | - | 137.70 | 0 | 1,089.14 | 0 |
| Gain On Sale Of Business | - | 137.70 | 0 | 1,089.14 | 0 |
| Restructuring And Mergern Acquisition | 0 | -127.85 | - | - | - |
| Total Other Finance Cost | -0.84 | -12.79 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc.this co. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Biohaven Ltd. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| Sionna Therapeutics, Inc. | SION | $1.7B | -22.66 | 5.56 | -24.5% | -18.75 |
| Taysha Gene Therapies, Inc. | TSHA | $1.7B |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| -15.53 |
| 6.85 |
| -44.1% |
| -13.39 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Peer Median | - | -8.93 | 5.49 | -34.3% | 0.51 | |